Literature DB >> 27050509

Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity.

Tania Løve Aaes1, Agnieszka Kaczmarek1, Tinneke Delvaeye2, Bram De Craene3, Stefaan De Koker4, Liesbeth Heyndrickx1, Iris Delrue1, Joachim Taminau3, Bartosz Wiernicki1, Philippe De Groote1, Abhishek D Garg5, Luc Leybaert6, Johan Grooten4, Mathieu J M Bertrand1, Patrizia Agostinis5, Geert Berx3, Wim Declercq1, Peter Vandenabeele7, Dmitri V Krysko1.   

Abstract

Successful immunogenic apoptosis in experimental cancer therapy depends on the induction of strong host anti-tumor responses. Given that tumors are often resistant to apoptosis, it is important to identify alternative molecular mechanisms that elicit immunogenic cell death. We have developed a genetic model in which direct dimerization of FADD combined with inducible expression of RIPK3 promotes necroptosis. We report that necroptotic cancer cells release damage-associated molecular patterns and promote maturation of dendritic cells, the cross-priming of cytotoxic T cells, and the production of IFN-γ in response to tumor antigen stimulation. Using both FADD-dependent and FADD-independent RIPK3 induction systems, we demonstrate the efficient vaccination potential of immunogenic necroptotic cells. Our study broadens the current concept of immunogenic cell death and opens doors for the development of new strategies in cancer therapy.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27050509     DOI: 10.1016/j.celrep.2016.03.037

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  140 in total

Review 1.  Necroptosis: A new way of dying?

Authors:  Britt Hanson
Journal:  Cancer Biol Ther       Date:  2016-07-19       Impact factor: 4.742

2.  Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression.

Authors:  Changlin Li; Hui Sun; Wei Wei; Qiuzi Liu; Yinglei Wang; Ying Zhang; Fuming Lian; Fangchao Liu; Chenchen Li; Kaicheng Ying; Hang Huo; Zhi Qi; Benyi Li
Journal:  Cell Oncol (Dordr)       Date:  2020-07-24       Impact factor: 6.730

Review 3.  To the edge of cell death and back.

Authors:  Yi-Nan Gong; Jeremy Chase Crawford; Bradlee L Heckmann; Douglas R Green
Journal:  FEBS J       Date:  2018-12-19       Impact factor: 5.542

4.  Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity.

Authors:  Annelise G Snyder; Nicholas W Hubbard; Michelle N Messmer; Sigal B Kofman; Cassidy E Hagan; Susana L Orozco; Kristy Chiang; Brian P Daniels; David Baker; Andrew Oberst
Journal:  Sci Immunol       Date:  2019-06-21

5.  The RIP3-RIP1-NF-κB signaling axis is dispensable for necroptotic cells to elicit cross-priming of CD8+ T cells.

Authors:  Junming Ren; Xian Jia; Yihao Zhao; Wenke Shi; Jiongcong Lu; Yingying Zhang; Jianfeng Wu; Bo Liang; Rui Wu; Guo Fu; Jiahuai Han
Journal:  Cell Mol Immunol       Date:  2017-06-19       Impact factor: 11.530

Review 6.  Immunogenic cell death in cancer and infectious disease.

Authors:  Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2016-10-17       Impact factor: 53.106

7.  A new mechanism for autophagy regulation of anti-tumor immune responses.

Authors:  Andrew Thorburn
Journal:  Autophagy       Date:  2020-09-05       Impact factor: 16.016

8.  Immunogenic necroptosis in the anti-tumor photodynamic action of BAM-SiPc, a silicon(IV) phthalocyanine-based photosensitizer.

Authors:  Ying Zhang; Ying-Kit Cheung; Dennis K P Ng; Wing-Ping Fong
Journal:  Cancer Immunol Immunother       Date:  2020-08-24       Impact factor: 6.968

Review 9.  The Microenvironment of Tongue Cancer.

Authors:  Want Tao; Zeng Li-Juan; Li Kan; Li Jing-Yuan; Liu Xiang-Qi; Liang Yu-Jie
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

10.  A caspase-independent way to kill cancer cells.

Authors:  Brent E Fitzwalter; Andrew Thorburn
Journal:  Nat Cell Biol       Date:  2017-08-31       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.